We here analyze factors influencing survival in 865 newly diagnosed mm patien.
Multiple myeloma survival with stem cell transplant.
A stem cell transplant replaces unhealthy blood cells with healthy ones.
Then the patient receives new healthy blood forming stem cells.
Older patients and those with low risk disease show the greatest gains over time while people with high risk factors showed the least change its researchers said.
All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back.
In a stem cell transplant the patient gets high dose chemotherapy to kill the cells in the bone marrow.
A population based study published correction appears in blood.
In allogeneic transplantation stem cells are given by a donor most commonly a brother or sister.
The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival.
It isn t a cure but compared to chemotherapy alone a.
Multiple myeloma survival rate after stem cell transplant.
People who have autologous or allogeneic transplants first receive high dose chemotherapy to kill the cancer cells.
The standard of care for fit multiple myeloma patients is to receive high dose chemotherapy hdt with autologous stem cell rescue otherwise known as autologous stem cell transplant asct after completion of induction therapy.
The transplant of this kind is the standard treatment for patients with various myeloma.
The long term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines a large review study reports.
Autologous stem cell transplantation is more common for multiple myeloma but either type of transplant can be used.
Stem cell transplant for multiple myeloma.
Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma.